- Psychedelics stock MindBio Therapeutics (CSE:MBIO) made a major discovery from sleep data from its LSD-microdosing trials
- The LSD-microdosing randomized controlled clinical trials yielded positive data including statistically significant enhancements in subjective feelings of “wellness,” “creativity,” “happiness,” “social connectivity” and “energy”
- The company confirmed positive sleep responses to MindBio’s LSD-microdosing treatment
- MindBio Therapeutics Stocks (CSE:MBIO) opened trading at $0.09 per share
Psychedelics stock MindBio Therapeutics (CSE:MBIO) made a major discovery from sleep data from its LSD-microdosing trials.
The Vancouver-based company’s LSD-microdosing randomized controlled clinical trials have yielded positive data, including statistically significant enhancements in subjective feelings of “wellness,” “creativity,” “happiness,” “social connectivity” and “energy.”
The company confirmed positive sleep responses to MindBio’s LSD-microdosing treatment. It said LSD-microdosing improves subjective mood feelings, and it has a statistically significant impact on quality of sleep.
The sleep data came from 80 clinical trial participants totalling 3,231 nights of sleep.
Data collected from the trial adds to MindBio’s intellectual property in a big data play for the company.
MindBio scientists are preparing seven more upcoming papers analysing data from Phase 1 LSD-microdosing randomized controlled trials in 80 healthy subjects ahead of two Phase 2 LSD-microdosing trials, which will begin soon.
The team recorded, measured, and analyzed the sleep patterns of participants in the LSD-microdosing treatment group against the placebo group.
MindBio is a biotech and biopharma company focused on creating treatments for mental health conditions. It is the first psychedelics stock in history to have clinical trials approved for LSD take-home use. The company’s CEO, Justin Hanka recently demonstrated how 1 million microdoses of LSD could potentially benefit tens of thousands of patients with depression. Click here to read more.
MindBio Therapeutics Corp. (CSE:MBIO) opened trading at $0.09 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.